Clinical trial
A Prospective, Open-label, Multicenter Study With Blinded Over-reading Characterizing the Efficacy and Safety of 99mTc-EC-DG in the Evaluation of Coronary Artery Disease (CAD)
NCT01899833 is registered in ClinicalTrials.gov with Cell>Point LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Open-label, Multicenter Study With Blinded Over-reading Characterizing the Efficacy and Safety of 99mTc-EC-DG in the Evaluation of Coronary Artery Disease (CAD)
- Lead sponsor
- Cell>Point LLC
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- May 10, 2025
- Completion date
- April 30, 2026
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.